2022 年 HIV-1 耐药突变更新。
2022 update of the drug resistance mutations in HIV-1.
机构信息
University Medical Center Utrecht, The Netherlands and Ezintsha, University of the Witwatersrand, Johannesburg, South Africa.
Pierre et Marie Curie University and Pitié-Salpêtrière Hospital, Paris, France.
出版信息
Top Antivir Med. 2022 Oct;30(4):559-574.
Abstract
The 2022 edition of the IAS-USA drug resistance mutations list updates the Figure last published in September 2019. The mutations listed are those that have been identified by specific criteria for evidence and drugs described. The Figure is designed to assist practitioners to identify key mutations associated with resistance to antiretroviral drugs, and therefore, in making clinical decisions regarding antiretroviral therapy.
摘要
2022 年版的 IAS-USA 耐药突变列表更新了最后一次发布于 2019 年 9 月的图表。列表中的突变是根据证据和描述的药物的具体标准确定的。该图表旨在帮助临床医生识别与抗逆转录病毒药物耐药相关的关键突变，从而做出抗逆转录病毒治疗的临床决策。
相似文献
1
2022 update of the drug resistance mutations in HIV-1.
Top Antivir Med. 2022 Oct;30(4):559-574.
2
2019 update of the drug resistance mutations in HIV-1.
Top Antivir Med. 2019 Sep;27(3):111-121.
3
2015 Update of the Drug Resistance Mutations in HIV-1.
Top Antivir Med. 2015 Oct-Nov;23(4):132-41.
4
Update of the Drug Resistance Mutations in HIV-1: 2005.
Top HIV Med. 2005 Mar-Apr;13(1):51-7.
5
Update of the drug resistance mutations in HIV-1: Fall 2005.
Top HIV Med. 2005 Oct-Nov;13(4):125-31.
6
2017 Update of the Drug Resistance Mutations in HIV-1.
Top Antivir Med. 2016 Dec;24(4):132-133.
7
Update of the drug resistance mutations in HIV-1: Fall 2006.
Top HIV Med. 2006 Aug-Sep;14(3):125-30.
8
Update of the Drug Resistance Mutations in HIV-1.
Top HIV Med. 2008 Dec;16(5):138-45.
9
2014 Update of the drug resistance mutations in HIV-1.
Top Antivir Med. 2014 Jun-Jul;22(3):642-50.
10
2011 update of the drug resistance mutations in HIV-1.
Top Antivir Med. 2011 Nov;19(4):156-64.
引用本文的文献
1
Synthesis of novel N1 functionalized diazepinone analogues a base-mediated C-N cross coupling reaction as reverse transcriptase inhibitors: theoretical and experimental investigations.
RSC Adv. 2025 Aug 18;15(36):29160-29175. doi: 10.1039/d5ra03504j.
2
Brief Report: HIV-1 Resistance Analysis of Participants With HIV-1 and Hepatitis B Initiating Therapy With Bictegravir/Emtricitabine/Tenofovir Alafenamide or Dolutegravir Plus Emtricitabine/Tenofovir Disoproxil Fumarate: A Subanalysis of ALLIANCE Data.
J Acquir Immune Defic Syndr. 2024 Aug 1;96(4):380-384. doi: 10.1097/QAI.0000000000003434. Epub 2024 Jun 21.
3
Mechanisms of Immune Evasion in HIV-1: The Role of Virus-Host Protein Interactions.
Curr Issues Mol Biol. 2025 May 16;47(5):367. doi: 10.3390/cimb47050367.
4
Unique molecular signatures in rebound viruses from antiretroviral drug and CRISPR-treated HIV-1-infected humanized mice.
Commun Biol. 2025 Jul 19;8(1):1077. doi: 10.1038/s42003-025-08499-6.
5
Advances in HIV Treatment and Vaccine Development: Emerging Therapies and Breakthrough Strategies for Long-Term Control.
AIDS Res Treat. 2025 Jul 4;2025:6829446. doi: 10.1155/arat/6829446. eCollection 2025.
6
Clinical and Health Care Resource Use Outcomes Associated With Resistance to Antiretroviral Therapy Among Veterans With HIV.
Open Forum Infect Dis. 2025 Jun 9;12(7):ofaf340. doi: 10.1093/ofid/ofaf340. eCollection 2025 Jul.
7
Integrative Computational Approaches for Understanding Drug Resistance in HIV-1 Protease Subtype C.
Viruses. 2025 Jun 16;17(6):850. doi: 10.3390/v17060850.
8
Strategies and efforts in circumventing the emergence of antiviral resistance against conventional antivirals.
NPJ Antimicrob Resist. 2025 Jun 9;3(1):54. doi: 10.1038/s44259-025-00125-z.
9
Evolutionary Sequence and Structural Basis for the Epistatic Origins of Drug Resistance in HIV.
bioRxiv. 2025 May 2:2025.04.30.651576. doi: 10.1101/2025.04.30.651576.
10
Treatment of Advanced HIV in the Modern Era.
Drugs. 2025 May 12. doi: 10.1007/s40265-025-02181-1.
本文引用的文献
1
Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection.
N Engl J Med. 2022 May 12;386(19):1793-1803. doi: 10.1056/NEJMoa2115542.
2
Impact of combinations of clinically observed HIV integrase mutations on phenotypic resistance to integrase strand transfer inhibitors (INSTIs): a molecular study.
J Antimicrob Chemother. 2022 Mar 31;77(4):979-988. doi: 10.1093/jac/dkab498.
3
Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-concept clinical study.
J Antimicrob Chemother. 2022 Mar 31;77(4):989-995. doi: 10.1093/jac/dkab503.
4
Lenacapavir: a first-in-class HIV-1 capsid inhibitor.
Curr Opin HIV AIDS. 2022 Jan 1;17(1):15-21. doi: 10.1097/COH.0000000000000713.
5
Clinical evidence for a lack of cross-resistance between temsavir and ibalizumab or maraviroc.
AIDS. 2022 Jan 1;36(1):11-18. doi: 10.1097/QAD.0000000000003097.
6
Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV.
N Engl J Med. 2021 Jul 22;385(4):330-341. doi: 10.1056/NEJMoa2101609.
7
Case Report: Emergent Resistance in a Treatment-Naive Person With Human Immunodeficiency Virus Under Bictegravir-Based Therapy.
Open Forum Infect Dis. 2021 Jun 4;8(6):ofab297. doi: 10.1093/ofid/ofab297. eCollection 2021 Jun.
8
Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083.
J Infect Dis. 2021 Nov 16;224(9):1581-1592. doi: 10.1093/infdis/jiab152.
9
Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis.
AIDS. 2021 Jul 15;35(9):1333-1342. doi: 10.1097/QAD.0000000000002883.
10
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Lancet. 2021 Dec 19;396(10267):1994-2005. doi: 10.1016/S0140-6736(20)32666-0. Epub 2020 Dec 9.
Zotero 插件